Long-term Function and Survival of Radicava ORS® (Oral Edaravone)-Treated Patients With ALS vs Propensity Score–Matched PRO-ACT Historical Controls (P8-2.003)
Investigate function and survival of Mitsubishi Tanabe Pharma America (MTPA) oral edaravone-treated patients enrolled in MTPA oral edaravone studies vs propensity score–matched Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) historical placebo patients.
Authors
- Art Wamil
- Stephen Apple (ORCID: https://orcid.org/0000-0002-3051-3953)
- Takatomo Yoneoka
- Angela Genge (ORCID: https://orcid.org/0000-0001-5587-9946)
- Yoshiteru Ushirogawa
- Noah J. Sasson (ORCID: https://orcid.org/0000-0002-3676-1253)
- Fumihiro Takahashi (ORCID: https://orcid.org/0000-0001-5701-5332)
- Daniel Selness
- Vesna Todorović
- Manabu Hirai
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Mitsubishi Tanabe Pharma Corporation
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210390
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00